A phase I trial of an oral subtype-selective histone deacetylase inhibitor, chidamide, in combination with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer

OBJECTIVE: This phase I study was to evaluate safety, maximum tolerated dose, pharmacokinetics and preliminary antitumor activity of chidamide, a novel subtype-selective histone deacetylase (HDAC) inhibitor, in combination with paclitaxel and carboplatin in patients with advanced non-small cell lung...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Xingsheng, Wang, Lin, Lin, Lin, Han, Xiaohong, Dou, Guifang, Meng, Zhiyun, Shi, Yuankai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5018540/
https://www.ncbi.nlm.nih.gov/pubmed/27647973
http://dx.doi.org/10.21147/j.issn.1000-9604.2016.04.08

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5018540/
https://www.ncbi.nlm.nih.gov/pubmed/27647973
http://dx.doi.org/10.21147/j.issn.1000-9604.2016.04.08

Ejemplares similares